Saudi Arabia Diabetes Drug Market Research Report: Forecast (2026-2032)

Market Definition

Diabetic drugs aid individuals afflicted with the disease to maintain their blood glucose levels. They cannot heal the patient but they reduce the likelihood of complications.

Market Insights & Analysis: Saudi Arabia Diabetes Drug Market (2026-2032):

The Saudi Arabia Diabetes Drug Market size was valued at around USD 499 million in 2025 and is projected to reach USD 740.2 million by 2032. Along with this, the market is estimated to grow at a CAGR of around 6.79% during the forecast period, i.e., 2026-32. The rate of diabetes is intensively increasing in the region which is creating the demand for the drugs. Also, the increasing spending on the healthcare system with government programs and support is further driving the demand for Diabetes drugs in Saudi Arabia. The government has also been focusing on providing insurance coverage for diseases and the incorporation of new technologies for cutting-edge treatment options for diabetes.

The youth in the region are at a higher risk for developing the disease currently leading to the increase in healthcare costs, adverse quality of life coupled with shorter life expectancy. The Saudi Arabian region is suffering from diabetes intensively as in about 10 people more than 1 is suffering from the disease and the ubiquity of the disease will almost double by 2045. Also, the report by the IDF indicates that around 1.86 million citizens in Saudi Arabia have diabetes but still not recognized yet. Currently, 4.27 million Saudi Arabian people have diabetes. This number is expected to grow to 5.6 million by 2030 and can reach 7.5 million by 2045. The ubiquity of diabetes is increasing in Saudi Arabia with unhealthy lifestyles and an increasingly obese population, ultimately creating a heavy demand for the Saudi Arabia Diabetes Drug Market.

By 2030, a 10% reduction is planned by Saudi Arabia in the ubiquity of diabetes. Moreover, they have provided multiple investments for diabetes drugs to promote market growth. For instance; Saudia Arabia provided 25-35% of their healthcare budget for various diseases like obesity and diabetes. It also included cardiovascular diseases caused due to adverse diabetes in the region. Other government initiatives include high taxation on sugary drinks and a focus on preventive diabetes care coupled with fitness programs. They imposed a 50% tax on various beverages containing high sugar, in the past few years. In addition to this, a 100% tax was also imposed on energy drinks. Combating diabetes by the government, along with the higher purchasing power of the people in the country, may help the market for diabetes drugs during the forecast period.

Saudi Arabia Diabetes Drug Market Scope:

Saudi Arabia Diabetes Drug Market Driver:

High Prevalence of Diabetes Propelling Market Growth

Due to genetic predispositions and unhealthy lifestyle choices, Saudi Arabia has one of the highest prevalence rates in the world. By 2026, around 24% of the total adult population of Saudi Arabia is expected to have Diabetes which was just around 17.7% in 2021. This rising prevalence is leading the nation to become the 2nd highest in the Middle East and 7th highest globally in diabetes occupancy. An unhealthy lifestyle has resulted in the prevalence of obesity-related problems in Saudi Arabia that majorly pose a threat to several chronic diseases like Type-2 diabetes. An approximate 35.4% of the adult population of Saudi Arabia suffers from obesity. This creates an immense nationwide demand for Diabetes Drugs for the treatment and prevention of diabetes, thereby significantly contributing to the market growth.

Another reason is the country has some of the highest per capita consumption of sugar-filled drinks which worsens the diabetes epidemic. High prevalence rates of the disease result from this sort of sedentary behavior allied with diets full of fat and sugar which fuels the growth of the Saudi Arabia Diabetes Drug Market.

Saudi Arabia Diabetes Drug Market Opportunity:

Rising Focus on Advanced Therapies

Saudi Arabia is seeing a rise in the use of several cutting-edge therapies including SGLT-2 inhibitors and basal insulin analogs coupled with GLP-1 receptors which presents several growth prospects. To lower obesity they aid in weight management, which is one of the main causes of diabetes in Saudi Arabia. Due to the high incidence of diabetes-related heart problems in Saudi Arabia SGLT-2 inhibitor drugs like Jardiance empagliflozin are gaining popularity because of their capacity to reduce blood sugar levels and the risk of cardiovascular complications. The shift is supported by Saudi Vision 2030 which places a strong emphasis on modernizing healthcare and guaranteeing access to it. The government can help pharmaceutical companies meet demand and enhance public health outcomes by increasing awareness among patients and adding coverage under insurance.

Saudi Arabia Diabetes Drug Market Challenge:

High Treatment Costs to Hinder Market Growth

High treatment costs are a huge challenge in the Saudi Arabia diabetes Drug Market. Advanced cures like GLP-1 receptor agonists can be very costly ultimately putting an economic burden on both patients and the healthcare system. Regardless of the availability of biosimilars, which provide an extra inexpensive opportunity, many patients still face challenges due to the high prices of brand-name medications. For instance; advanced insulins like Lantus and Novorapid remain costly, especially for the ones without comprehensive insurance coverage. The government’s healthcare initiatives aim to cope with these costs by introducing measures to reduce treatment expenses and increase access to crucial medications. However, affordability remains a vital barrier for many patients.

Saudi Arabia Diabetes Drug Market Trend:

Increasing Penetration of Biosimilar Insulins

Biosimilar insulins are becoming popular in Saudi Arabia due to their cost-effectiveness and equivalence to branded insulin analogs. The alternative options ensure the cost-effective provision of vital diabetes medications without compromising on accessibility. Biosimilar insulin is often priced lower than its branded counterpart and may even be up to 10–30% cheaper. This has been triggered by the Saudi Arabian government's health care reforms, increased number of diabetic patients, and measures to enhance prudent use of health care. Although biosimilar insulins still lag behind branded insulins in terms of market share, the footprint is rapidly increasing, and an approximate 10% market share in the insulin segment in Saudi Arabia has been estimated. The adoption of biosimilar insulins also demonstrates Saudi Arabia's desire to balance cost management with high-quality diabetes care. This fits within the broader healthcare reforms, where sustainable treatment solutions can be provided to the growing diabetic population in the country.

Saudi Arabia Diabetes Drug Market (2026-32): Segmentation Analysis

The Saudi Arabia Diabetes Drug Market study of MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2026–2032 at the global, regional, and national levels. Based on the analysis, the market has been further classified as:

Based on Insulins:

• Basal
• Bolous
• Traditional Insulins
• Biosimilar Insulins

Within the insulin segment, basal insulin dominates the Saudi Arabia Diabetes Drugs Market, accounting for approximately 48.75% of the total market share. This category includes leading long-acting insulin brands such as Lantus, Levemir, and Tresiba, which are widely prescribed due to their ability to maintain stable blood glucose levels over an extended duration. Moreover, basal insulin is strongly preferred in Saudi clinical practice because of its proven efficacy in managing both Type 1 and Type 2 diabetes, particularly in patients requiring consistent overnight and fasting glucose control.

Additionally, the demand for basal insulin is expected to remain high, as a large majority of diabetes patients in Saudi Arabia have Type 2 diabetes, which often progresses to stages where long-acting insulin becomes essential for effective glycemic regulation. Furthermore, government-supported diabetes awareness programs and structured care initiatives encourage early diagnosis and improved treatment adherence, which directly supports sustained adoption of basal insulin therapies across the country.

Based on the Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Clinics and Diabetes Centers

Based on distribution channel, hospital pharmacies lead the Saudi Arabia Diabetes Drugs Market, holding approximately 45.2% share of the total market. This dominance is primarily driven by their strong integration with hospital-based diabetes care, especially for patients requiring specialized treatment for severe complications or advanced therapies such as insulin and injectable antidiabetic drugs. Moreover, hospital pharmacies are closely linked with specialist-led treatment pathways, where endocrinologists and diabetes care experts prescribe and dispense therapies that are often not widely available through standard retail outlets.

Additionally, public hospitals operating under the Saudi Ministry of Health (MoH) play a critical role in boosting hospital pharmacy volumes, as essential diabetes medicines are frequently provided at subsidized rates or free of cost, improving affordability and adherence. Furthermore, hospitals act as key implementation centers for chronic disease management programs, where drug dispensing is supported by structured follow-ups, patient education, and lifestyle interventions. Hence, the combination of specialist availability, access to advanced therapies, and government-backed affordability programs continues to make hospital pharmacies the most preferred and relied-upon distribution channel for diabetes drugs in Saudi Arabia.

Saudi Arabia Diabetes Drug Market (2026-32): Regional Projection

Geographically, the Saudi Arabia Diabetes Drug Market expands across:

• Northern
• Central
• Southern
• Eastern
• Western

Based on region, Central Saudi Arabia leads the Diabetes Drugs Market, accounting for approximately 40.5% of the overall market share. This dominance is largely supported by the region’s high urban population concentration and strong population density, which are closely associated with higher diabetes prevalence due to sedentary lifestyles, limited physical activity, and changing dietary habits. Moreover, Central Saudi Arabia offers superior access to advanced healthcare infrastructure, including specialized hospitals, endocrinologists, and diabetes care centers, enabling timely diagnosis and stronger treatment continuity.

Additionally, the region witnesses more structured and aggressive diabetes management initiatives, supported by awareness campaigns and screening programs, which further increases treatment uptake. Furthermore, major urban hubs such as Riyadh benefit from relatively higher per capita income levels, allowing patients to afford a broader range of therapies. As a result, demand is stronger not only for standard oral antidiabetic drugs but also for premium treatments such as insulin analogs and combination therapies, reinforcing the central region’s leadership in the Saudi diabetes drugs landscape.

Saudi Arabia Diabetes Drug Industry Recent Development:

• 2025: Saudi Arabia inaugurated its first local insulin manufacturing facility, a landmark step toward pharmaceutical self-sufficiency under Vision 2030. The facility is positioned to strengthen domestic availability of insulin and reduce dependence on imports.
• 2024: During the Global Health Exhibition 2024 in Riyadh, NUPCO, Sudair Pharmaceutical Co., Sanofi, and Novo Nordisk signed the final agreement to localize the production of selected insulin products in Saudi Arabia. This development aligns with Vision 2030 goals of pharmaceutical localization and supply security.
• October 2024: Novo Nordisk A/S announced an agreement with Lifera. Through Lifera’s subsidiary, SaudiBio, the two companies have agreed to localize insulin production in Saudi Arabia.
• August 2024: Boehringer Ingelheim and Alpha Pharma collaborated to localize the production of one of its Type 2 Diabetes Medicines in Saudi Arabia. Alpha Pharma, aims to combat type 2 diabetes in the Kingdom and is fully aligned with the Kingdom’s Vision 2030 pillars.

Gain a Competitive Edge with Our Saudi Arabia Diabetes Drug Market Report

• Saudi Arabia Diabetes Drug Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
• This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
• Saudi Arabia Diabetes Drug Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.

Gain a Competitive Edge with Our Saudi Arabia Diabetes Drug Market Report

1. Saudi Arabia Diabetes Drug Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps business organizations to gain a holistic understanding of market dynamics & make informed decisions.
2. This report also highlights current market trends & future projections, allowing business organizations to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
3. The Saudi Arabia Diabetes Drug Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, business organizations can develop strategies to minimize risks & optimize their operations.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.